DYNS SEC filings, in plain English
Everything Senti Biosciences Holdings, Inc. has filed with the SEC that we hold — 40 filings, newest first, 5 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: On August 14, 2026, Senti Holdings issued $4.0 million in Senior Secured Convertible Notes to Celadon Partners SPV 24 under the April 27, 2026 Securities Purchase Agreement. The filing also references a potential merger of a Celadon affiliate into Senti Holdings with contingent value rights up to $60.0 million tied to SENTI-202 regulatory and sales milestones. Why it matters: This adds $4.0 million in secured convertible debt and advances a proposed Celadon-affiliated merger with a $60.0 million CVR structure, with a preliminary proxy already filed on July 21, 2026. The transaction structure and milestone-based payout represent a significant post-SPAC restructuring event for DYNS shareholders.
What changed: Q2 2026 10-Q of Senti Biosciences Holdings, Inc. (Nasdaq: SNTI). Cash and equivalents fell to $6,463 thousand from $16,420 thousand at December 31, 2025, with restricted cash of $1,426 thousand; total assets were $33,105 thousand versus $51,223 thousand and total liabilities $36,506 thousand versus $45,634 thousand, so stockholders' equity turned to a $(3,401) thousand deficit from $5,589 thousand. Why it matters: Equity crossed into deficit during the half-year and cash covers roughly half a quarter at the current burn as reported. Much of the improvement in the six-month loss is a one-time lease-modification gain, and GeneFab related-party items run through revenue, costs, receivables and sublease income.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“(Continued) (Unaudited) the Company’s liquidity, the Company concluded that substantial doubt continued to exist and that the Company’s cash and cash equivalents of $ 6.5 million as of June 30, 2026, were not sufficient for the”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: PREM14A by SENTI BIOSCIENCES HOLDINGS, INC., the post-combination successor carried on SpacBrain's Dynamics Special Purpose Corp. record — a preliminary proxy for the 2026 annual meeting on August 18, 2026, record date July 23, 2026, not a de-SPAC registration. Six proposals: three Class I directors, KPMG ratification, a Nasdaq 5635(d) issuance of over 19.99% of outstanding common stock on exchange of subsidiary Senti Holdings, Inc.'s Senior Secured Convertible Notes, an Agreement and Plan of Merger dated July 14, 2026, a reverse stock split, and adjournment. Why it matters: Under that merger agreement, among Parent, Merger Sub, the Company, Midco and Opco, Merger Sub merges into Midco and each Midco share converts into the right to receive Milestone Payment Amounts, distributed to the Company's equityholders as contractual contingent value rights, one CVR per outstanding Company share — consideration is contingent, not a fixed share count. Opco licenses or assigns the intellectual property and contracts for the Rett Syndrome and TIL programs. The reverse split ratio is a range of 1-for-20 to 1-for-50 at the board's discretion.
What changed: Senti Biosciences, the Dynamics Special Purpose Corp. successor, filed as additional proxy material the same Agreement and Plan of Merger dated July 14, 2026 among Celadon Partners SPV 35 Limited, Senti Merger Sub, Inc., Senti Biosciences Holding, Inc., Senti Holdings, Inc. and Senti Biosciences, Inc. that it filed on Form 8-K the same day. The document sets out the merger mechanics, effect on capital stock and merger consideration, equity award treatment, and a vote required section confirming stockholder approval is a condition. Why it matters: Filing the merger agreement under Schedule 14A as well as on Form 8-K puts it before stockholders as soliciting material, which confirms the transaction goes to a vote rather than being completed by written consent or tender. For holders of the former DYNS equity that vote is the only point of leverage, and the merger consideration and equity award treatment sections are the two places to check before deciding — neither figure is visible in the captured text, so confidence here is limited.
outside datenothing moved · 1 with no prior record of ours
- Outside date
- 2026-12-31 · unchanged
The clause …“a right to terminate the Merger Agreement if the Merger is not completed by December 31, 2026 (the “Outside Date”). In addition, the Company may terminate the Merger Agreement if Parent or an affiliate of Parent fails to fund and”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Senti Biosciences, the Dynamics Special Purpose Corp. successor, filed as Exhibit 2.1 an Agreement and Plan of Merger dated July 14, 2026 among Celadon Partners SPV 35 Limited, Senti Merger Sub, Inc., Senti Biosciences Holding, Inc., Senti Holdings, Inc. and Senti Biosciences, Inc. It provides for the merger, closing and effective time, the effect on capital stock and payment of merger consideration, treatment of company equity awards, and sections on the vote required and anti-takeover provisions. Why it matters: An acquisition by a private SPV rather than a strategic buyer, structured with a merger sub and a required stockholder vote, means public holders of the former DYNS equity are being taken out for consideration fixed in the agreement rather than continuing as shareholders. The sections on the effect on capital stock and on company equity awards are where that consideration and the treatment of options sit; they are named in the captured text but their figures are not, so the price cannot be established from this excerpt.
outside datenothing moved · 1 with no prior record of ours
- Outside date
- not previously extracted2026-12-31
SpacBrain reads this as the agreement may be terminated from 2026-12-31.
The clause …“a right to terminate the Merger Agreement if the Merger is not completed by December 31, 2026 (the “Outside Date”). In addition, the Company may terminate the Merger Agreement if Parent or an affiliate of Parent fails to fund and”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“trials for its product candidates in development. The Company concluded that substantial doubt continued to exist and that the Company’s cash and cash equivalents of $ 8.9 million as of March 31, 2026, were not sufficient for the”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“• Our history of recurring losses and anticipated expenditures raises substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern requires that we obtain sufficient funding to”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.